• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

固相萃取-快速高效液相色谱-紫外检测法测定血浆中米那普仑的浓度及其在大鼠体内的药代动力学研究

Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat.

机构信息

Centre for Drug Research, Universiti Sains Malaysia, 11800, Penang, Malaysia.

出版信息

Anal Bioanal Chem. 2010 Jul;397(5):2023-30. doi: 10.1007/s00216-010-3707-7. Epub 2010 May 8.

DOI:10.1007/s00216-010-3707-7
PMID:20454783
Abstract

A new solid phase extraction method for rapid high performance liquid chromatography-UV determination of mitragynine in plasma has been developed. Optimal separation was achieved with an isocratic mobile phase consisting of acetonitrile-ammonium acetate buffer, 50 mM at pH 5.0 (50:50, v/v). The method had limits of detection and quantification of 0.025 and 0.050 microg/mL, respectively. The method was accurate and precise for the quantitative analysis of mitragynine in human and rat plasma with within-day and between-day accuracies between 84.0 and 109.6%, and their precision values were between 1.7 and 16.8%. Additional advantages over known methods are related to the solid phase extraction technique for sample preparation which yields a clean chromatogram, a short total analysis time, requires a smaller amount of plasma samples and has good assay sensitivity for bioanalytical application. The method was successfully applied in pharmacokinetic and stability studies of mitragynine. In the present study, mitragynine was found to be fairly stable during storage and sample preparation. The present study showed for the first time the detailed pharmacokinetic profiles of mitragynine. Following intravenous administration, mitragynine demonstrated a biphasic elimination from plasma. Oral absorption of the drug was slow, prolonged and was incomplete, with a calculated absolute oral bioavailability value of 3.03%. The variations observed in previous pharmacokinetic studies after oral administration of mitragynine could be attributed to its poor bioavailability rather than to the differences in assay method, metabolic saturation or mitragynine dose.

摘要

已开发出一种新的固相萃取方法,用于快速高效液相色谱-紫外法测定血浆中的帽柱草碱。采用等度流动相,由乙腈-乙酸铵缓冲液(50 mM,pH 5.0,50:50,v/v)组成,可实现最佳分离。该方法的检测限和定量限分别为 0.025 和 0.050 μg/mL。该方法准确、精密,可用于人及大鼠血浆中帽柱草碱的定量分析,日内和日间准确度在 84.0%至 109.6%之间,精密度值在 1.7%至 16.8%之间。与已知方法相比,该方法的优点还在于固相萃取技术用于样品制备,可得到干净的色谱图,总分析时间短,所需血浆样品量少,且具有良好的生物分析应用检测灵敏度。该方法成功应用于帽柱草碱的药代动力学和稳定性研究。在本研究中,发现帽柱草碱在储存和样品制备过程中相当稳定。本研究首次详细描述了帽柱草碱的药代动力学特征。静脉注射后,帽柱草碱从血浆中呈双相消除。药物口服吸收缓慢、延长且不完全,绝对口服生物利用度值为 3.03%。口服给予帽柱草碱后,先前药代动力学研究中观察到的变化可能归因于其较差的生物利用度,而不是检测方法、代谢饱和或帽柱草碱剂量的差异。

相似文献

1
Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat.固相萃取-快速高效液相色谱-紫外检测法测定血浆中米那普仑的浓度及其在大鼠体内的药代动力学研究
Anal Bioanal Chem. 2010 Jul;397(5):2023-30. doi: 10.1007/s00216-010-3707-7. Epub 2010 May 8.
2
A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats.一种用于测定血清中帽柱木碱的高效液相色谱法及其在大鼠药代动力学研究中的应用。
Biomed Chromatogr. 2007 Feb;21(2):176-83. doi: 10.1002/bmc.731.
3
Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.大鼠口服帽柱木( kratom)叶提取物后帽柱木碱的比较药代动力学
Planta Med. 2019 Mar;85(4):340-346. doi: 10.1055/a-0770-3683. Epub 2018 Nov 16.
4
Optimization and validation of RP-HPLC-UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: application to pharmacokinetic study.采用固相萃取的反相高效液相色谱-紫外检测法测定人及兔血浆中丁胺喹的方法优化与验证:在药代动力学研究中的应用
Biomed Chromatogr. 2008 May;22(5):535-41. doi: 10.1002/bmc.965.
5
Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics.采用液相色谱-串联质谱法测定大鼠血浆中帽柱木碱:在药代动力学中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 15;877(24):2593-7. doi: 10.1016/j.jchromb.2009.06.023. Epub 2009 Jun 21.
6
A validated HPLC-ESI-MS/MS method for quantification of 2-hydroxy-4-methoxy benzoic acid from rat plasma and its application to pharmacokinetic study using sparse sampling methodology.一种经过验证的用于定量大鼠血浆中2-羟基-4-甲氧基苯甲酸的高效液相色谱-电喷雾串联质谱法及其在使用稀疏采样方法的药代动力学研究中的应用。
J Pharm Biomed Anal. 2014 Nov;100:190-198. doi: 10.1016/j.jpba.2014.08.002. Epub 2014 Aug 10.
7
A simple and sensitive HPLC-UV method for the determination of ponicidin in rat plasma and its application in a pharmacokinetic study.一种用于测定大鼠血浆中ponicidin的简单灵敏的高效液相色谱-紫外检测法及其在药代动力学研究中的应用。
Biomed Chromatogr. 2011 Mar;25(3):362-6. doi: 10.1002/bmc.1456.
8
Understanding the physicochemical properties of mitragynine, a principal alkaloid of Mitragyna speciosa, for preclinical evaluation.了解帽柱木碱(一种东革阿里主要生物碱)的理化性质,用于临床前评估。
Molecules. 2015 Mar 18;20(3):4915-27. doi: 10.3390/molecules20034915.
9
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method.通过一种新的液相色谱/串联质谱定量方法对地西他滨(5-氮杂-2'-脱氧胞苷)的分解产物以及临床前和低剂量临床药代动力学进行表征。
Rapid Commun Mass Spectrom. 2006;20(7):1117-26. doi: 10.1002/rcm.2423.
10
[Determination of evodiamine and rutaecarpine of compound Wuzhuyu cataplasm in plasma by SPE-HPLC: application to its pharmacokinetics].固相萃取-高效液相色谱法测定复方吴茱萸巴布剂中吴茱萸碱和吴茱萸次碱在血浆中的含量及其药代动力学研究
Zhongguo Zhong Yao Za Zhi. 2009 Nov;34(22):2946-9.

引用本文的文献

1
In vitro skin permeation of mitragynine: Optimisation of antioxidants for enhanced drug stability and formulation performance.帽柱木碱的体外皮肤渗透:用于提高药物稳定性和制剂性能的抗氧化剂优化
Drug Deliv Transl Res. 2025 Aug 16. doi: 10.1007/s13346-025-01933-6.
2
Quantification of 11 kratom alkaloids including mitragynine and its main metabolites in human plasma using LC-MS/MS.使用液相色谱-串联质谱法对人血浆中包括帽柱木碱及其主要代谢物在内的11种 kratom 生物碱进行定量分析。
Anal Bioanal Chem. 2025 Feb;417(4):761-769. doi: 10.1007/s00216-024-05689-9. Epub 2024 Dec 7.
3
Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers.
伊曲康唑对健康志愿者中帽柱木碱和7-羟基帽柱木碱药代动力学的影响。
ACS Pharmacol Transl Sci. 2024 Feb 20;7(3):823-833. doi: 10.1021/acsptsci.3c00335. eCollection 2024 Mar 8.
4
Precipitated withdrawal with kratom use following naltrexone administration.纳曲酮给药后使用 kratom 引发的戒断反应。
Ment Health Clin. 2023 Jun 28;13(3):155-158. doi: 10.9740/mhc.2023.06.155. eCollection 2023 Jun.
5
Translating Kratom-Drug Interactions: From Bedside to Bench and Back.译:从床边到实验台,再回到床边:浅谈阿片类药物与咔哇的相互作用。
Drug Metab Dispos. 2023 Aug;51(8):923-935. doi: 10.1124/dmd.122.001005. Epub 2023 Jun 7.
6
Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry.超高效液相色谱-串联质谱法同时测定相思树叶子提取物和商业产品中的十种关键卡痛生物碱。
Drug Test Anal. 2019 Aug;11(8):1162-1171. doi: 10.1002/dta.2604. Epub 2019 May 15.
7
: Clinical, Toxicological Aspects and Analysis in Biological and Non-Biological Samples.临床、毒理学方面以及生物和非生物样本分析
Medicines (Basel). 2019 Mar 4;6(1):35. doi: 10.3390/medicines6010035.
8
A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdue.对亨宁菲尔德、法恩特和王(2018年)的回应:对 kratom(一种植物)进行监管行动早就该进行了。
Psychopharmacology (Berl). 2019 Mar;236(3):861-863. doi: 10.1007/s00213-018-5112-4. Epub 2018 Nov 10.
9
Lateral Flow Assessment and Unanticipated Toxicity of Kratom.阿片类药物替代物(K 粉)的横向评估和意外毒性
Chem Res Toxicol. 2019 Jan 22;32(1):113-121. doi: 10.1021/acs.chemrestox.8b00218. Epub 2018 Nov 16.
10
The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.根据《管制物质法案》的 8 个因素评估咔哇潮饮的滥用潜力:对管制和研究的影响。
Psychopharmacology (Berl). 2018 Feb;235(2):573-589. doi: 10.1007/s00213-017-4813-4. Epub 2017 Dec 23.